DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20172752

Drug utilization study in ischaemic heart disease in a tertiary care hospital, Mangalore, India

Tittu George Zachariah, Subramanyam K., Pooja M., Vinayak J. Kempaller

Abstract


Background: The study of drug utilization is a component of a medical audit and periodic evaluation need to be done to enable suitable modifications in prescription of drugs to increase the therapeutic benefit and decrease the adverse effects. When new drugs are used additional information on safety and efficacy may be generated. Ischaemic heart disease (IHD) is a condition in which there is an inadequate supply of blood and oxygen to a portion of the myocardium. Medications for IHD include anti-platelet therapy, nitrates, statins, ACE inhibitors, beta blockers, CCB’s, diuretics.

Methods: The study was carried out at cardiology department of K. S. Hegde Charitable Hospital for a period of one year from January 2015, and relevant retrospective data were also collected from hospital records for period pertaining to one year from 1/1/2013.

Results: We assessed discharge summaries of 950 patients and found that majority of patients were males than females. The highest number of patients were in the age group of 51-60 years. Polypharmacy has been observed in our study. The average number of days spent by the patients in the hospital was 3.5 days. None of the drugs were prescribed using generic names, all the drugs (100%) were prescribed in brand names only. Common co-morbidities associated with IHD were hypertension and diabetes. Most commonly prescribed drugs for IHD were Aspirin, followed by Atorvastatin, Clopidogrel, and Nitrates.

Conclusions: In our study, on analysing the drug prescription data it was observed that there was no statistically significant change in drug utilization between the two years.


Keywords


Anti-platelet therapy, Drug utilisation study, Ischaemic heart disease, Polypharmacy

Full Text:

PDF

References


Wiholm BE, Westerholm B. Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden. Acta Med Scand Suppl. 1984;683:107- 17.

WHO Int WG for Drug Statistics Methodology. Introduction to Drug Utilization Research. Solutions. 2003;1-48.

Strom BL, Kimmel SE, Hennessy S. Pharmacoepidemiology, 5th Edition; 2012:1-953.

Laporte J, Porta M, Capella D. Drug utilization studies: a tool for determining the effectiveness of drug use. Br J Clin Pharmacol. 1983;16(3):301-4.

Hogerzeil HV. Promoting rational prescribing: an international perspective. Br J Clin Pharmacol. 1995;39(1):1-6.

Antman EM, Andrew P, Selwyn JL. Harrison’s principles of internal medicine. - 18th Ed.; 2012:1998-2014.

Ockene JK, Kuller LH, Svendsen KH, Meilahn E. The relationship of smoking cessation to coronary heart disease and lung cancer in the {Multiple Risk Factor Intervention Trial (MRFIT)}. Am J Public Heal. 1990;80(8):954-8.

Spinar J. Hypertension and Ischaemic Heart Disease. Cor Et Vasa. 2012.

Menotti A, Blackburn H, Kromhout D, Nissinen A, Fidanza F, Giampaoli S, et al. Changes in population cholesterol levels and coronary heart disease deaths in seven countries. Eur Hear J. 1997;18(4):566-71.

Garcia MJ, McNamara PM, Gordon T, Kannell WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow up study. Diabetes. 1974;23(2):105-11.

Frikke-Schmidt R, Nordestgaard BG, Jensen GB, Steffensen R, TybjrgHansen A. Genetic variation in ABCA1 predicts Ischaemic heart disease in the general population. Arterioscler Thromb Vasc Biol. 2008;28(1):180-6.

Kokkinos PF, Fernhall B. Physical activity and high-density lipoprotein cholesterol levels: what is the relationship? Sports Med. 1999;28(5):307-14.

Phillips GB, Castelli WP, Abbott RD, McNamara PM. Association of hyperestrogenemia and coronary heart disease in men in the Framingham cohort. Am J Med. 1983 May;74(5):863-9.

Jenkins CD, Rosenman RH, Zyzanski SJ. Prediction of clinical coronary heart disease by a test for the coronary-prone behavior pattern. N Engl J Med. 1974 Jun 6;290(23):1271-5.

Roerecke M, Rehm J. Irregular heavy drinking occasions and risk of Ischaemic heart disease: a systematic review and meta-analysis. Am J Epidemiol. 2010 Mar 15;171(6):633-44.

Tanis BC, van den Bosch MA, Kemmeren JM, Cats VM, Helmerhorst FM, Algra A, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med. 2001 Dec 20;345(25):1787-93.

Thomas Michel BBH. Goodman & Gilman’s pharmacological basis of therapeutics. - 12th Ed.; 2011:745-788.

Dawalji S, Venkateshwarlu K, Thota S, Venisetty PK, Kumar R. Prescribing Pattern in Coronary Artery Disease: A Prospective Study. 2015;3:24-33.

Kumar M, Dahiya V, Mishra S, Sharma D, Mishra N, Lahkar M. Cardiovascular disease prevalence and drug utilization patterns at a tertiary care hospital in northeastern India. Int J Pharm Pharm Sci. 2016;8(6):116-9.

George J, Devi P, Kamath DY, Anthony N, Kunnoor NS, Sanil SS. Patterns and determinants of cardiovascular drug utilization in coronary care unit patients of a tertiary care hospital. J Cardiovasc Dis Res. 2013;4(4):214-21.

Xavier D, Pais P, Devereaux PJ, Xie C, Prabhakaran D, Reddy KS, et al. Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet (London, England). 2008 Apr;371(9622):1435-42.

Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA. 1997 Jan;277(4):301-6.

Pradeepa R, Mohan V. Hypertension & pre-hypertension in developing countries. Indian J Med Res. 2008 Dec;128(6):688-90.

Rodgers A, Lawes C, MacMahon S. Reducing the global burden of blood pressure-related cardiovascular disease. J Hypertens Suppl. 2000 May;18(1):S3-6.

Ajay VS, Prabhakaran D. Coronary heart disease in Indians: Implications of the inter heart study. Indian J of Med Res. 2010;132:561-6.

Balady GJ, Williams MA, Ades PA, Bittner V, Comoss P, Foody JM, et al. Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils O. Circulation. 2007 May;115(20):2675-82.

Banerjee S, Kumar V, Ramachandran PKA. Does the pharmacological management of unstable angina vary with age and gen der - a descriptive study. J Clin Diagnostic Res. 2010;(4):3150-7.